Global Med Technologies(R), Inc. Files Post Effective Amendment Related to Previously Registered Shares
2007年6月2日 - 9:30AM
PRニュース・ワイアー (英語)
DENVER, June 1 /PRNewswire-FirstCall/ -- Global Med
Technologies(R), Inc. ("Global Med" or the "Company") (OTC:GLOB)
(BULLETIN BOARD: GLOB) , today announced that it has filed a post
effective amendment related to previously registered shares. This
registration statement does not provide for the issuance of any
additional common shares but seeks to maintain registration on the
common shares underlying the Series A Convertible Preferred Stock
("Series A") and the warrants issued as part of the financing
agreement that took place in December of 2005. This financing
eliminated $814,000 in annual dividend and interest payments and
approximately 4.86 million shares of the Company's common stock.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO )
The Company's Chairman and CEO, Michael I. Ruxin, M.D., commented,
"This post effective registration statement seeks to maintain
registration on warrants and the Series A issued as part of the
December 2005 financing and provides for no further dilution."
About Global Med Technologies, Inc. Global Med Technologies, Inc.
is an international e-Health medical information technology company
providing information management software products and services to
the healthcare industry. Its Wyndgate Technologies division is a
leading supplier of information management systems to U.S. and
International blood centers and hospital transfusion centers. Each
year, Wyndgate's products and services manage more than eight
million blood components, representing over 27% of the U.S. blood
supply. Wyndgate's products are being used in Canada and
sub-Saharan Africa, and are being implemented in the Caribbean.
Together, the SafeTrace Tx*(R) advanced transfusion management
system and the SafeTrace(R) donor management system provide
Vein-to-Vein(R) tracking from donor collection to patient
transfusion. For more information about Global Med's products and
services, please call 800-WYNDGATE or visit
http://www.globalmedtech.com/, http://www.peoplemed.com/ and
http://www.wyndgate.com/. This news release may include statements
that constitute forward-looking statements, usually containing the
words "believe," "estimate," "project," "expects" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release. *Patent Pending Company Contact: Investor
Contact: Global Med Technologies, Inc. Paul Holm Michael I. Ruxin,
M.D. H.L. Lanzet (303) 238-2000 (212) 888-4570
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies,
Inc., +1-303-238-2000; or Investors, Paul Holm, , or H.L. Lanzet,
both for Global Med Technologies, Inc., +1-212-888-4570 Web site:
http://www.globalmedtech.com/ http://www.peoplemed.com/
http://www.wyndgate.com/
Copyright